{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:51:02Z","timestamp":1783774262603,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary central nervous system lymphoma is a rare subtype of non\u2010Hodgkin lymphoma that is confined to the brain, leptomeninges, or the eye and is associated with a relatively poor prognosis compared to other extranodal diffuse large B\u2010cell lymphomas. However, methotrexate\u2010based induction chemotherapy followed by consolidative chemotherapy or high\u2010dose therapy and autologous stem cell transplantation is associated with improved survival and reduced neurotoxicity. Aberrant activation of B\u2010cell receptor signaling and activation of nuclear factor kappa beta is a frequent genetic alteration and offers opportunities for targeted therapies in this lymphoma subtype.<\/jats:p>","DOI":"10.1002\/hon.2598","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T08:00:51Z","timestamp":1560326451000},"page":"15-18","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Primary central nervous system lymphoma: A curable disease"],"prefix":"10.1002","volume":"37","author":[{"given":"Tracy T.","family":"Batchelor","sequence":"first","affiliation":[{"name":"Department of Neurology Brigham and Women's Hospital and Harvard Medical School, Dana\u2010Farber\/Harvard Cancer Center, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos218"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.357"},{"key":"e_1_2_2_4_1","volume-title":"WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_2_5_1","article-title":"Introduction of novel agents in the treatment of primary CNS lymphoma","author":"Grommes C","year":"2018","journal-title":"Neuro Oncol"},{"key":"e_1_2_2_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.524"},{"key":"e_1_2_2_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0210"},{"key":"e_1_2_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.09.139"},{"key":"e_1_2_2_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.2941"},{"key":"e_1_2_2_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21583"},{"key":"e_1_2_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2004.10.002"},{"key":"e_1_2_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)90538-S"},{"key":"e_1_2_2_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1561"},{"key":"e_1_2_2_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.013"},{"key":"e_1_2_2_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61416-1"},{"key":"e_1_2_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00036-3"},{"key":"e_1_2_2_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.4910"},{"key":"e_1_2_2_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318297eeba"},{"key":"e_1_2_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21824"},{"key":"e_1_2_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70229-1"},{"key":"e_1_2_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601472"},{"key":"e_1_2_2_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.036"},{"key":"e_1_2_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30747-2"},{"key":"e_1_2_2_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016077907952"},{"key":"e_1_2_2_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0649-7"},{"key":"e_1_2_2_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820f2d94"},{"key":"e_1_2_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30174-6"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2598","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2598","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T08:32:57Z","timestamp":1694334777000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":26,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1002\/hon.2598"],"URL":"https:\/\/doi.org\/10.1002\/hon.2598","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"2019-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}